



3.4.1 Internal Medicine and Systemic Diseases Group

Publications: 9

Impact Factor: 43.⁰⁷²

Q1: 3



Research Activity

Publications

- Arenzana CB, Marhuenda AR, Mozo AN, Abanades CS, Robles EM, Blanco JJR. Macitentan for the treatment of severe digital ulcers in a patient with mixed connective tissue disease: avoiding drug interactions. *Clin Exp Rheumatol*. 2020; 38(1): 171. Letter. IF: 4.473; Q2
- Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Monserrat-Villatoro J, Quintana M, Figueira JC, Santos-Olmo RMT, García-Rodríguez J, Martín-Vega A, Buño A, Ramírez E, Martínez-Ales G, García-Arenzana N, Núñez MC, Martí-de-Gracia M, Ramos FM, Reinoso-Barbero F, Martín-Quirós A, Núñez AR, Mingorance J, Segura CJC, Arribas DP, Cuevas ER, Sánchez CP, Ríos JJ, Hernan MA, Frías J, Arribas JR. A Cohort of patients with COVID-19 in a major teaching hospital in Europe. *J Clin Med*. 2020; 9(6): 1733. Article. IF: 4.241; Q1
- Casas-Rojo JM, Anton-Santos JM, Millan-Núñez-Cortes J, Lumbreras-Bermejo C, Ramos-Rincon JM, Roy-Vallejo E, Artero-Mora A, Arnalich-Fernández F, García-Brunen JM, Vargas-Núñez JA, Freire-Castro S, Manzano-Espinosa L, Perales-Fraile I, Crestelo-Viéitez A, Puchades-Gimeno F, Rodilla-Sala E, Solís-Marquinez MN, Bonet-Tur D, Fidalgo-Moreno MP, Fonseca-Aizpuru EM, Carrasco-Sánchez FJ, Rabadan-Pejenaute E, Rubio-Rivas M, Torres-Pena JD, Gómez-Huelgas R. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry. *Rev Clin Esp*. 2020; 220(8):480-94. Article. IF: 1.556; Q3
- de la Fuente M, Sánchez C, Vallejo C, Díaz-del Cerro E, Arnalich F, Hernanz A. Vitamin C and

vitamin C plus E improve the immune function in the elderly. *Exp Gerontol*. 2020; 142: 111118. Article. IF: 4.032; Q2

- García-Broncano P, Medrano LM, Berenguer J, Brochado-Kith O, González-García J, Jiménez-Sousa A, Quereda C, Sanz J, Téllez MJ, Díaz L, Jiménez JL, Resino S, Carrero A, Miralles P, López JC, Parras F, Padilla B, Aldámiz-Echevarría T, Tejerina F, Díez C, Pérez-Latorre L, Fanciulli C, Gutiérrez I, Ramírez M, Carretero S, Bellon JM, Bermejo J, Berenguer J, Hontañón V, Arribas JR, Montes ML, Bernardino I, Pascual JF, Zamora F, Pena JM, Arnalich F, Díaz M, González-García J, Domingo P, Guardiola JM, Van den Eynde E, Pérez M, Ribera E, Crespo M, Casado JL, Dronda F, Moreno A, Pérez-Elias MJ, Sanfrutos MA, Moreno S, Quereda C, Arranz A, Casas E, de Miguel J, Schroeder S, Sanz J, Santos I, Bustinduy MJ, Iribarren JA, Rodríguez-Arondo F, Von-Wichmann MA, Vergas J, Téllez MJ, Vinuesa D, Muñoz L, Hernández-Quero J, Ferrer A, Galindo MJ, Ortiz L, Ortega E, Montero M, Blanes M, Cuellar S, Lacniz J, Salavert M, López-Aldeguez J, Pérez G, Gaspar G, Yllescas M, Crespo P, Aznar E, Esteban H. Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study. *J Infect*. 2020; 80(1): 99-110. Article. IF: 6.072; Q1
- Ramos-Ramos JC, Lázaro-Perona F, Arribas JR, García-Rodríguez J, Mingorance J, Ruiz-Carrascoso G, Borobia AM, Pano-Pardo JR, Herruzo R, Arnalich F. Proof-of-concept trial of the combination of lactitol with *Bifidobacterium bifidum* and *Lactobacillus acidophilus* for the eradication of intestinal OXA-48-producing En-

terobacteriaceae. *Gut Pathogens*. 2020; 12(1): 15. Article. IF: 4.181; Q2

- Robles-Marhuenda A, Álvarez-Troncoso J, Rodríguez-Pena R, Busca-Arenzana C, López-Granados E, Arnalich-Fernández F. Chronic granulomatous disease: Single-center Spanish experience. *Clin Immunol*. 2020; 211: 108323. Article. IF: 3.969; Q3
- Rubio-Rivas M, Corbella X, Guillén-del-Castillo A, Vilella CT, Arguilles DC, Argibay A, Hitos JAV, Parra JAT, González-Echavarrri C, Ortego-Centeno N, Martínez LT, Carbalreira MR, Ballve AM, Salas XP, Fraile IP, Chamorro AJ, Vuelta ABM, Freire M, Muñoz MR, García AG, del Campo IPM, García MES, Bello DB, Espinosa G, Hernández FJG, Comet LS, Blanco JJR, Giménez RAFD, Trigo SS, Pla VF, Aznar CPS. Spanish scleroderma risk score (RESCLESORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation. *Autoimmun Rev*. 2020; 19(5): 102507. Review. IF: 9.754; D1
- Solans-Laqué R, Rodríguez-Carballeira M, Ríos-Blanco JJ, Fraile G, Saez-Comet L, Martínez-Zapico A, Frutos B, Solanich X, Fonseca-Aizpuru E, Pasquau-Liano F, Zamora M, Oristrell J, Fanlo P, López-Dupla M, Abdilla M, García-Sánchez I, Sopena B, Castillo MJ, Perales I, Callejas JL. Comparison of the Birmingham vasculitis activity score and the five-factor score to assess survival in antineutrophil cytoplasmic antibody-associated vasculitis: A study of 550 patients from Spain (REVAS Registry). *Arthritis Care Res*. 2020; 72(7): 1001-10. Article. IF: 4.794; Q2

Research projects

Montiel López C, Arnalich Fernández F. Resistance to chemotherapy and EGFR-targeted therapy induced by tobacco use through nicotinic receptors in non-small cell lung cancer: in vitro, in vivo and patient studies (SAF2017-82689-R). Ministerio de Economía, Industria y Competitividad. 2018-2020.

Management centre: UAM

Ríos Blanco JJ. Estudio de la relación entre la rigidez arteril y la función endotelial en pacientes con hipertensión de bata blanca. Menarini Diagnósticos S. A. 2009-Ongoing.

Management centre: FIBHULP

Clinical trials

Arnalich Fernández, F. Ensayo clínico del uso de anakinra (Anti il-1) en el síndrome de tormenta de citoquinas secundario a covid-19.

Type: EECC, phase II.

HULP code: 5589.

Sponsored's protocol code: ANA-COVID-GEAS.

Sponsored by: Fundación Miguel Servet-Instituto de Investigaciones Biomédicas.

Signed date: 01/05/2020

